Evidence map›Paper›PMID 32107321›Full record

ArticleNeurology2020

Education Research: Multiple sclerosis and neuroimmunology fellowship training status in the United States.

Ahmed Z Obeidat, Yasir N Jassam, Le H Hua, Gary Cutter, Corey C Ford, June Halper, Robert P Lisak, Nancy L Sicotte, Erin E Longbrake

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neurology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.6field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 8 institutions in 1 country.

Ahmed Z ObeidatFrom the Department of Neurology (A.Z.O.), Medical College of Wisconsin, Milwaukee; Department of Neurology (Y.N.J.), The University of Kansas, Kansas City; Cleveland Clinic Lou Ruvo Center for Brain Health (L.H.H.), Las Vegas, NV; Department of Biostatistics (G.C.), University of Alabama at Birmingham; Department of Neurology (C.F.), University of New Mexico, Albuquerque; The Consortium of Multiple Sclerosis Centers and International Organization of Multiple Sclerosis Nurses (J.H.), Multiple Sclerosis Nurses International Certification Board, Hackensack, NJ; Departments of Neurology, Biochemistry, Microbiology, and Immunology (R.P.L.), School of Medicine, Wayne State University and Detroit Medical Center, MI; Department of Neurology (N.L.S.), Cedars-Sinai Medical Center, Los Angeles, CA; and Center for Neuroepidemiology and Clinical Neurological Research (E.E.L.), Yale School of Medicine (E.E.L.), Yale University, New Haven, CT. aobeidat@mcw.edu.
Yasir N JassamFrom the Department of Neurology (A.Z.O.), Medical College of Wisconsin, Milwaukee; Department of Neurology (Y.N.J.), The University of Kansas, Kansas City; Cleveland Clinic Lou Ruvo Center for Brain Health (L.H.H.), Las Vegas, NV; Department of Biostatistics (G.C.), University of Alabama at Birmingham; Department of Neurology (C.F.), University of New Mexico, Albuquerque; The Consortium of Multiple Sclerosis Centers and International Organization of Multiple Sclerosis Nurses (J.H.), Multiple Sclerosis Nurses International Certification Board, Hackensack, NJ; Departments of Neurology, Biochemistry, Microbiology, and Immunology (R.P.L.), School of Medicine, Wayne State University and Detroit Medical Center, MI; Department of Neurology (N.L.S.), Cedars-Sinai Medical Center, Los Angeles, CA; and Center for Neuroepidemiology and Clinical Neurological Research (E.E.L.), Yale School of Medicine (E.E.L.), Yale University, New Haven, CT.
Le H HuaFrom the Department of Neurology (A.Z.O.), Medical College of Wisconsin, Milwaukee; Department of Neurology (Y.N.J.), The University of Kansas, Kansas City; Cleveland Clinic Lou Ruvo Center for Brain Health (L.H.H.), Las Vegas, NV; Department of Biostatistics (G.C.), University of Alabama at Birmingham; Department of Neurology (C.F.), University of New Mexico, Albuquerque; The Consortium of Multiple Sclerosis Centers and International Organization of Multiple Sclerosis Nurses (J.H.), Multiple Sclerosis Nurses International Certification Board, Hackensack, NJ; Departments of Neurology, Biochemistry, Microbiology, and Immunology (R.P.L.), School of Medicine, Wayne State University and Detroit Medical Center, MI; Department of Neurology (N.L.S.), Cedars-Sinai Medical Center, Los Angeles, CA; and Center for Neuroepidemiology and Clinical Neurological Research (E.E.L.), Yale School of Medicine (E.E.L.), Yale University, New Haven, CT.
Gary CutterFrom the Department of Neurology (A.Z.O.), Medical College of Wisconsin, Milwaukee; Department of Neurology (Y.N.J.), The University of Kansas, Kansas City; Cleveland Clinic Lou Ruvo Center for Brain Health (L.H.H.), Las Vegas, NV; Department of Biostatistics (G.C.), University of Alabama at Birmingham; Department of Neurology (C.F.), University of New Mexico, Albuquerque; The Consortium of Multiple Sclerosis Centers and International Organization of Multiple Sclerosis Nurses (J.H.), Multiple Sclerosis Nurses International Certification Board, Hackensack, NJ; Departments of Neurology, Biochemistry, Microbiology, and Immunology (R.P.L.), School of Medicine, Wayne State University and Detroit Medical Center, MI; Department of Neurology (N.L.S.), Cedars-Sinai Medical Center, Los Angeles, CA; and Center for Neuroepidemiology and Clinical Neurological Research (E.E.L.), Yale School of Medicine (E.E.L.), Yale University, New Haven, CT.
Corey C FordFrom the Department of Neurology (A.Z.O.), Medical College of Wisconsin, Milwaukee; Department of Neurology (Y.N.J.), The University of Kansas, Kansas City; Cleveland Clinic Lou Ruvo Center for Brain Health (L.H.H.), Las Vegas, NV; Department of Biostatistics (G.C.), University of Alabama at Birmingham; Department of Neurology (C.F.), University of New Mexico, Albuquerque; The Consortium of Multiple Sclerosis Centers and International Organization of Multiple Sclerosis Nurses (J.H.), Multiple Sclerosis Nurses International Certification Board, Hackensack, NJ; Departments of Neurology, Biochemistry, Microbiology, and Immunology (R.P.L.), School of Medicine, Wayne State University and Detroit Medical Center, MI; Department of Neurology (N.L.S.), Cedars-Sinai Medical Center, Los Angeles, CA; and Center for Neuroepidemiology and Clinical Neurological Research (E.E.L.), Yale School of Medicine (E.E.L.), Yale University, New Haven, CT.
June HalperFrom the Department of Neurology (A.Z.O.), Medical College of Wisconsin, Milwaukee; Department of Neurology (Y.N.J.), The University of Kansas, Kansas City; Cleveland Clinic Lou Ruvo Center for Brain Health (L.H.H.), Las Vegas, NV; Department of Biostatistics (G.C.), University of Alabama at Birmingham; Department of Neurology (C.F.), University of New Mexico, Albuquerque; The Consortium of Multiple Sclerosis Centers and International Organization of Multiple Sclerosis Nurses (J.H.), Multiple Sclerosis Nurses International Certification Board, Hackensack, NJ; Departments of Neurology, Biochemistry, Microbiology, and Immunology (R.P.L.), School of Medicine, Wayne State University and Detroit Medical Center, MI; Department of Neurology (N.L.S.), Cedars-Sinai Medical Center, Los Angeles, CA; and Center for Neuroepidemiology and Clinical Neurological Research (E.E.L.), Yale School of Medicine (E.E.L.), Yale University, New Haven, CT.
Robert P LisakFrom the Department of Neurology (A.Z.O.), Medical College of Wisconsin, Milwaukee; Department of Neurology (Y.N.J.), The University of Kansas, Kansas City; Cleveland Clinic Lou Ruvo Center for Brain Health (L.H.H.), Las Vegas, NV; Department of Biostatistics (G.C.), University of Alabama at Birmingham; Department of Neurology (C.F.), University of New Mexico, Albuquerque; The Consortium of Multiple Sclerosis Centers and International Organization of Multiple Sclerosis Nurses (J.H.), Multiple Sclerosis Nurses International Certification Board, Hackensack, NJ; Departments of Neurology, Biochemistry, Microbiology, and Immunology (R.P.L.), School of Medicine, Wayne State University and Detroit Medical Center, MI; Department of Neurology (N.L.S.), Cedars-Sinai Medical Center, Los Angeles, CA; and Center for Neuroepidemiology and Clinical Neurological Research (E.E.L.), Yale School of Medicine (E.E.L.), Yale University, New Haven, CT.
Nancy L SicotteFrom the Department of Neurology (A.Z.O.), Medical College of Wisconsin, Milwaukee; Department of Neurology (Y.N.J.), The University of Kansas, Kansas City; Cleveland Clinic Lou Ruvo Center for Brain Health (L.H.H.), Las Vegas, NV; Department of Biostatistics (G.C.), University of Alabama at Birmingham; Department of Neurology (C.F.), University of New Mexico, Albuquerque; The Consortium of Multiple Sclerosis Centers and International Organization of Multiple Sclerosis Nurses (J.H.), Multiple Sclerosis Nurses International Certification Board, Hackensack, NJ; Departments of Neurology, Biochemistry, Microbiology, and Immunology (R.P.L.), School of Medicine, Wayne State University and Detroit Medical Center, MI; Department of Neurology (N.L.S.), Cedars-Sinai Medical Center, Los Angeles, CA; and Center for Neuroepidemiology and Clinical Neurological Research (E.E.L.), Yale School of Medicine (E.E.L.), Yale University, New Haven, CT.
Erin E LongbrakeFrom the Department of Neurology (A.Z.O.), Medical College of Wisconsin, Milwaukee; Department of Neurology (Y.N.J.), The University of Kansas, Kansas City; Cleveland Clinic Lou Ruvo Center for Brain Health (L.H.H.), Las Vegas, NV; Department of Biostatistics (G.C.), University of Alabama at Birmingham; Department of Neurology (C.F.), University of New Mexico, Albuquerque; The Consortium of Multiple Sclerosis Centers and International Organization of Multiple Sclerosis Nurses (J.H.), Multiple Sclerosis Nurses International Certification Board, Hackensack, NJ; Departments of Neurology, Biochemistry, Microbiology, and Immunology (R.P.L.), School of Medicine, Wayne State University and Detroit Medical Center, MI; Department of Neurology (N.L.S.), Cedars-Sinai Medical Center, Los Angeles, CA; and Center for Neuroepidemiology and Clinical Neurological Research (E.E.L.), Yale School of Medicine (E.E.L.), Yale University, New Haven, CT.
University of Alabama at Birmingham · USCedars-Sinai Medical Center · USDetroit Medical Center · USMedical College of Wisconsin · USMultiple Sclerosis Foundation · USUniversity of Kansas · USUniversity of New Mexico · USWayne State University · US

Funding

Interactions between Gut Microbiome and B-Cell Depletion in Multiple SclerosisK23NS107624 · NINDS · YALE UNIVERSITY · PI LONGBRAKE, ERIN · 2019 to 2023
$980k
6 · The paper itself

Abstract

objectiveTo investigate the current status of postgraduate training in neuroimmunology and multiple sclerosis (NI/MS) in the United States.

methodsWe developed a questionnaire to collect information on fellowship training focus, duration of training, number of fellows, funding application process, rotations, visa sponsorship, and an open-ended question about challenges facing training in NI/MS. We identified target programs and sent the questionnaires electronically to fellowship program directors.

resultsWe identified and sent the questionnaire to 69 NI/MS fellowship programs. We successfully obtained data from 64 programs. Most programs were small, matriculating 1-2 fellows per year, and incorporated both NI and MS training into the curriculum. Most programs were flexible in their duration, typically lasting 1-2 years, and offered opportunities for research during training. Only 56% reported the ability to sponsor nonimmigrant visas. Most institutions reported having some internal funding, although the availability of these funds varied from year to year. Several program directors identified funding availability and the current absence of national subspecialty certification as major challenges facing NI/MS training.

conclusionOur study is the first to describe the current status of NI/MS training in the United States. We found many similarities across programs. We anticipate that these data will serve as a first step towards developing a standard NI/MS curriculum and help identify areas where shared resources could enhance trainee education despite differences in training environments. We identified funding availability, certification status, and nonimmigrant visa sponsorship as potential barriers to future growth in the field.

Indexed as

Education, Medical, GraduateFellowships and ScholarshipsMultiple SclerosisAllergy and ImmunologyCurriculumHumansNeurologySurveys and QuestionnairesTraining SupportUnited States

Identifiers

PMID32107321
PMCPMC9246053
OpenAlexW3007441115

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.